Stocktoria
Autolus Therapeutics plc AUTL
Autolus Therapeutics plc (AUTL) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $75.4M at a -381.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.615 |
| Retained earnings / assets | -2.354 |
| EBIT / assets | -0.459 |
| Equity / liabilities | 0.433 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AUTL | Autolus Therapeutics plc | 2/9 | -6.27 | — | +644.9% |
| RXRX | RECURSION PHARMACEUTICALS, INC. | 3/9 | -1.13 | — | +26.9% |
| CGEN | COMPUGEN LTD | 6/9 | -0.84 | 5.6 | +161.1% |
| BDTX | Black Diamond Therapeutics, Inc. | 6/9 | -0.83 | 4.4 | — |
| MGTX | MeiraGTx Holdings plc | 2/9 | -14.65 | — | +144.6% |
| VIR | Vir Biotechnology, Inc. | 2/9 | -0.97 | — | -7.6% |
| FDMT | 4D Molecular Therapeutics, Inc. | 3/9 | 6.96 | — | — |
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
FAQ
Is AUTL financially healthy?
Autolus Therapeutics plc's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does AUTL pay a dividend?
No, Autolus Therapeutics plc does not currently pay a dividend.
How profitable is AUTL?
In FY2025, Autolus Therapeutics plc had a net margin of -381.4% and a return on equity of -161.4%.
What is the analyst price target for AUTL?
The average Wall-Street price target for Autolus Therapeutics plc is $8.71, about 310.9% above the recent price, from 9 analysts.
Is AUTL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Autolus Therapeutics plc: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.